Amerigen Pharmaceuticals, Inc.
http://www.amerigenpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amerigen Pharmaceuticals, Inc.
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
ANI Grabs 23 US Products From Amerigen
In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice